Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK

Phase 1 Completed 24 enrolled Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study was to investigate the pharmacokinetic (PK) and safety of M2951 (Bruton's tyrosine kinase \[BTK\] inhibitor) in participants with different degrees of hepatic impairment compared to participants with normal hepatic function.

Timeline

Start: 2020-09-30
Primary completion: 2021-05-16
Completion: 2021-05-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Evobrutinib	Small molecule	30 mg	Oral

Indications

No indication recorded.